Daraxonrasib nearly doubled survival in advanced metastatic pancreatic cancer patients in a trial The drug targets KRAS mutations, found in over 90% of pancreatic tumors, improving treatment options Phase 3 trial showed median survival of 13.2 months with daraxonrasib versus 6.6 months with chemo